{"analyses":[{"ciLowerLimit":"-3.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"14.9","estimateComment":"Risk difference (% Arm A - Arm B) based on Cochran-Mantel-Haenszel test with adjustment for randomization stratification factors as recorded in IXRS.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.2248","paramType":"Risk Difference (RD)","paramValue":"5.8","statisticalComment":"Based on Cochran-Mantel-Haenszel test with adjustment for randomization stratification factors as recorded in IXRS.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"117"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"155"}],"units":"Participants"}],"description":"IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)","groups":[{"description":"Acalabrutinib 100 mg orally twice a day","id":"OG000","title":"Arm A: Acalabrutinib Monotherapy"},{"description":"Idelalisib+Rituximab or Bendamustine + Retuximab","id":"OG001","title":"Arm B: Investigator's Choice"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-treat population including all randomized participants","reportingStatus":"POSTED","timeFrame":"IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up","title":"IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis","type":"SECONDARY","unitOfMeasure":"Participants"}